Medical device, diagnostics and biotech firms should collaborate and share intellectual property early to better address the complicated health problems they are aiming to treat, former FDA director Dr. Andrew von Eschenbach said in a speech Monday in Massachusetts. Von Eschenbach also urged that changes be made to the FDA, including adding a layer of regulation driven by industry.

Related Summaries